DELCATH SYSTEMS, INC. cotiza a 15.32 USD y tiene una capitalización bursátil de $532M. En los últimos 12 meses ha facturado $95M con un margen de flujo de caja libre del 24.6%. Cotiza a 30.4 veces su flujo de caja libre (P/FCF) y a un PER de 999.2. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while cont…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.07 | $-0.03 | $-0.05 |
| Estimado | $-0.07 | $-0.09 | $-0.09 | $-0.03 |
| Sorpresa | — | +177.8% | +66.7% | -66.7% |
| Métrica | DCTH | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 86.2% | 57.0% | +29.1% |
| Operating Margin | 0.8% | -38.6% | +39.4% |
| Net Margin | 3.2% | -33.6% | +36.7% |
| FCF Margin | 24.6% | -13.9% | +38.5% |
| ROE | 2.4% | -40.4% | +42.8% |
| ROA | 2.2% | -32.0% | +34.2% |
| Current Ratio | 10.92 | 2.84 | +8.08 |
| Debt / Equity | — | 0.28 | — |